Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 296

1.

New On-Water Test for the Assessment of Blood Lactate Response to Exercise in Elite Kayakers.

Pilotto AM, Rasica L, Scalise G, Annoni S, LA Torre A, Marzorati M, Porcelli S.

Med Sci Sports Exerc. 2019 Dec;51(12):2595-2602. doi: 10.1249/MSS.0000000000002077.

PMID:
31246717
2.

CTBP1 depletion on prostate tumors deregulates miRNA/mRNA expression and impairs cancer progression in metabolic syndrome mice.

Dalton GN, Massillo C, Scalise GD, Duca R, Porretti J, Farré PL, Gardner K, Paez A, Gueron G, De Luca P, De Siervi A.

Cell Death Dis. 2019 Apr 1;10(4):299. doi: 10.1038/s41419-019-1535-z.

3.

CTBP1/CYP19A1/estradiol axis together with adipose tissue impacts over prostate cancer growth associated to metabolic syndrome.

Massillo C, Dalton GN, Porretti J, Scalise GD, Farré PL, Piccioni F, Secchiari F, Pascuali N, Clyne C, Gardner K, De Luca P, De Siervi A.

Int J Cancer. 2019 Mar 1;144(5):1115-1127. doi: 10.1002/ijc.31773. Epub 2018 Oct 9.

PMID:
30152543
4.

CTBP1 and metabolic syndrome induce an mRNA and miRNA expression profile critical for breast cancer progression and metastasis.

Farré PL, Scalise GD, Duca RB, Dalton GN, Massillo C, Porretti J, Graña K, Gardner K, De Luca P, De Siervi A.

Oncotarget. 2018 Feb 13;9(17):13848-13858. doi: 10.18632/oncotarget.24486. eCollection 2018 Mar 2.

5.

CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome disease.

Porretti J, Dalton GN, Massillo C, Scalise GD, Farré PL, Elble R, Gerez EN, Accialini P, Cabanillas AM, Gardner K, De Luca P, De Siervi A.

Int J Cancer. 2018 Aug 15;143(4):897-906. doi: 10.1002/ijc.31379. Epub 2018 Mar 30.

6.

CtBP1 associates metabolic syndrome and breast carcinogenesis targeting multiple miRNAs.

De Luca P, Dalton GN, Scalise GD, Moiola CP, Porretti J, Massillo C, Kordon E, Gardner K, Zalazar F, Flumian C, Todaro L, Vazquez ES, Meiss R, De Siervi A.

Oncotarget. 2016 Apr 5;7(14):18798-811. doi: 10.18632/oncotarget.7711.

7.

Tuberculosis: medico-legal aspects.

Vetrugno G, De-Giorgio F, D'Alessandro F, Scafetta I, Berloco F, Buonsenso D, Abbate F, Scalise G, Pascali VL, Valentini P.

Mediterr J Hematol Infect Dis. 2014 Apr 19;6(1):e2014033. doi: 10.4084/MJHID.2014.033. eCollection 2014. Review.

8.

[Durability and tolerability of long-term nevirapine-based HAART].

Giacometti A, Butini L, Cirioni O, Costantini A, Montroni M, Scalise G.

Infez Med. 2010 Mar;18(1):20-6. Italian.

9.

OpuC--an ABC transporter that is associated with Staphylococcus aureus pathogenesis.

Kiran MD, Akiyoshi DE, Giacometti A, Cirioni O, Scalise G, Balaban N.

Int J Artif Organs. 2009 Sep;32(9):600-10.

PMID:
19856269
10.

Anidulafungin in combination with amphotericin B against Aspergillus fumigatus.

Spreghini E, Orlando F, Santinelli A, Pisa E, Loretelli C, Manso E, Milici ME, Scalise G, Barchiesi F.

Antimicrob Agents Chemother. 2009 Sep;53(9):4035-9. doi: 10.1128/AAC.00659-09. Epub 2009 Jul 13.

11.

In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes.

Simonetti O, Ganzetti G, Arzeni D, Campanati A, Marconi B, Silvestri C, Cirioni O, Gabrielli E, Lenci I, Kamysz W, Kamysz E, Giacometti A, Scalise G, Barchiesi F, Offidani A.

Peptides. 2009 Oct;30(10):1794-7. doi: 10.1016/j.peptides.2009.06.033. Epub 2009 Jul 8.

PMID:
19591887
12.

In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes.

Simonetti O, Arzeni D, Ganzetti G, Silvestri C, Cirioni O, Gabrielli E, Castelletti S, Kamysz W, Kamysz E, Scalise G, Offidani A, Barchiesi F.

Br J Dermatol. 2009 Aug;161(2):249-52. doi: 10.1111/j.1365-2133.2009.09166.x. Epub 2009 Apr 29.

PMID:
19438437
13.

Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis.

Cirioni O, Silvestri C, Ghiselli R, Orlando F, Riva A, Gabrielli E, Mocchegiani F, Cianforlini N, Trombettoni MM, Saba V, Scalise G, Giacometti A.

Crit Care Med. 2009 Apr;37(4):1403-7. doi: 10.1097/CCM.0b013e31819c3e22.

PMID:
19318826
14.

In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents.

Barchiesi F, Silvestri C, Arzeni D, Ganzetti G, Castelletti S, Simonetti O, Cirioni O, Kamysz W, Kamysz E, Spreghini E, Abruzzetti A, Riva A, Offidani AM, Giacometti A, Scalise G.

Med Mycol. 2009 May;47(3):321-6. doi: 10.1080/13693780802641920. Epub 2008 Dec 27.

PMID:
19115137
15.

Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi.

Maida CM, Milici ME, Trovato L, Oliveri S, Amodio E, Spreghini E, Scalise G, Barchiesi F.

J Clin Microbiol. 2008 Dec;46(12):4071-4. doi: 10.1128/JCM.01088-08. Epub 2008 Oct 15.

16.

Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection.

Cirioni O, Silvestri C, Ghiselli R, Orlando F, Riva A, Mocchegiani F, Chiodi L, Castelletti S, Gabrielli E, Saba V, Scalise G, Giacometti A.

J Antimicrob Chemother. 2008 Dec;62(6):1332-8. doi: 10.1093/jac/dkn393. Epub 2008 Sep 16.

PMID:
18799470
17.

Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis.

Cirioni O, Ghiselli R, Silvestri C, Kamysz W, Orlando F, Riva A, Kamysz E, Castelletti S, Rocchi M, Saba V, Scalise G, Giacometti A.

Antimicrob Agents Chemother. 2008 Dec;52(12):4351-5. doi: 10.1128/AAC.00086-08. Epub 2008 Sep 8.

18.

Efficacy of the amphibian peptide distinctin in a neutropenic mouse model of staphylococcal sepsis.

Cirioni O, Ghiselli R, Orlando F, Silvestri C, De Luca S, Salzano AM, Mocchegiani F, Saba V, Scalise G, Scaloni A, Giacometti A.

Crit Care Med. 2008 Sep;36(9):2629-33. doi: 10.1097/CCM.0b013e318184430d.

PMID:
18679116
19.

In vitro and in vivo activity of aurintricarboxylic acid preparations against Cryptosporidium parvum.

Klein P, Cirioni O, Giacometti A, Scalise G.

J Antimicrob Chemother. 2008 Nov;62(5):1101-4. doi: 10.1093/jac/dkn303. Epub 2008 Jul 23.

PMID:
18653486
20.

Structural features of distinctin affecting peptide biological and biochemical properties.

Dalla Serra M, Cirioni O, Vitale RM, Renzone G, Coraiola M, Giacometti A, Potrich C, Baroni E, Guella G, Sanseverino M, De Luca S, Scalise G, Amodeo P, Scaloni A.

Biochemistry. 2008 Jul 29;47(30):7888-99. doi: 10.1021/bi800616k. Epub 2008 Jul 3.

PMID:
18597491
21.

BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection.

Orlando F, Ghiselli R, Cirioni O, Minardi D, Tomasinsig L, Mocchegiani F, Silvestri C, Skerlavaj B, Riva A, Muzzonigro G, Saba V, Scalise G, Zanetti M, Giacometti A.

Peptides. 2008 Jul;29(7):1118-23. doi: 10.1016/j.peptides.2008.03.005. Epub 2008 Mar 14.

PMID:
18430491
22.

Efficacy of LL-37 and granulocyte colony-stimulating factor in a neutropenic murine sepsis due to Pseudomonas aeruginosa.

Cirioni O, Ghiselli R, Tomasinsig L, Orlando F, Silvestri C, Skerlavaj B, Riva A, Rocchi M, Saba V, Zanetti M, Scalise G, Giacometti A.

Shock. 2008 Oct;30(4):443-8. doi: 10.1097/SHK.0b013e31816d2269.

PMID:
18391859
23.

RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus.

Simonetti O, Cirioni O, Ghiselli R, Goteri G, Scalise A, Orlando F, Silvestri C, Riva A, Saba V, Madanahally KD, Offidani A, Balaban N, Scalise G, Giacometti A.

Antimicrob Agents Chemother. 2008 Jun;52(6):2205-11. doi: 10.1128/AAC.01340-07. Epub 2008 Apr 7.

24.

Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.

Spreghini E, Maida CM, Tomassetti S, Orlando F, Giannini D, Milici ME, Scalise G, Barchiesi F.

Antimicrob Agents Chemother. 2008 Jun;52(6):1929-33. doi: 10.1128/AAC.00130-08. Epub 2008 Apr 7.

25.

Discovery of a quorum-sensing inhibitor of drug-resistant staphylococcal infections by structure-based virtual screening.

Kiran MD, Adikesavan NV, Cirioni O, Giacometti A, Silvestri C, Scalise G, Ghiselli R, Saba V, Orlando F, Shoham M, Balaban N.

Mol Pharmacol. 2008 May;73(5):1578-86. doi: 10.1124/mol.107.044164. Epub 2008 Feb 26.

PMID:
18314496
26.

Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model.

Simonetti O, Cirioni O, Goteri G, Ghiselli R, Kamysz W, Kamysz E, Silvestri C, Orlando F, Barucca C, Scalise A, Saba V, Scalise G, Giacometti A, Offidani A.

Peptides. 2008 Apr;29(4):520-8. doi: 10.1016/j.peptides.2007.12.011. Epub 2008 Jan 3.

PMID:
18255189
27.

Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis.

Ghiselli R, Giacometti A, Cirioni O, Mocchegiani F, Orlando F, Silvestri C, Di Matteo F, Abbruzzetti A, Scalise G, Saba V.

Crit Care Med. 2008 Jan;36(1):240-5.

PMID:
18090372
28.

In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp.

Barchiesi F, Giacometti A, Cirioni O, Arzeni D, Kamysz W, Silvestri C, Licci A, Marigliano A, Della Vittoria A, Nadolski P, Łukasiak J, Scalise G.

J Chemother. 2007 Oct;19(5):514-8.

PMID:
18073150
29.

Tachyplesin III and granulocyte-colony stimulating factor enhance the efficacy of tazobactam/piperacillin in a neutropenic mouse model of polymicrobial peritonitis.

Cirioni O, Ghiselli R, Kamysz W, Orlando F, Silvestri C, Mocchegiani F, Di Matteo F, Kamysz E, Riva A, Rocchi M, Saba V, Scalise G, Giacometti A.

Peptides. 2008 Jan;29(1):31-8. Epub 2007 Nov 6.

PMID:
18068869
30.

Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.

Spreghini E, Maida CM, Milici ME, Scalise G, Barchiesi F.

Antimicrob Agents Chemother. 2008 Feb;52(2):513-7. Epub 2007 Dec 3.

31.

The antimicrobial peptide tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model.

Minardi D, Ghiselli R, Cirioni O, Giacometti A, Kamysz W, Orlando F, Silvestri C, Parri G, Kamysz E, Scalise G, Saba V, Giovanni M.

Peptides. 2007 Dec;28(12):2293-8. Epub 2007 Oct 7.

PMID:
18022289
32.

Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection.

Ghiselli R, Giacometti A, Cirioni O, Mocchegiani F, Silvestri C, Orlando F, Kamysz W, Licci A, Nadolski P, Della Vittoria A, Łukasiak J, Scalise G, Saba V.

JPEN J Parenter Enteral Nutr. 2007 Nov-Dec;31(6):463-8.

PMID:
17947600
33.

RNAIII-inhibiting peptide affects biofilm formation in a rat model of staphylococcal ureteral stent infection.

Cirioni O, Ghiselli R, Minardi D, Orlando F, Mocchegiani F, Silvestri C, Muzzonigro G, Saba V, Scalise G, Balaban N, Giacometti A.

Antimicrob Agents Chemother. 2007 Dec;51(12):4518-20. Epub 2007 Sep 17.

34.

PCR real time assays for the early detection of BKV-DNA in immunocompromised patients.

Marinelli K, Bagnarelli P, Gaffi G, Trappolini S, Leoni P, Paggi AM, Della Vittoria A, Scalise G, Varaldo PE, Menzo S.

New Microbiol. 2007 Jul;30(3):275-8.

35.

Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin.

Milici ME, Maida CM, Spreghini E, Ravazzolo B, Oliveri S, Scalise G, Barchiesi F.

J Clin Microbiol. 2007 Nov;45(11):3529-33. Epub 2007 Aug 29.

36.

In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans.

Barchiesi F, Giacometti A, Cirioni O, Arzeni D, Silvestri C, Kamysz W, Abbruzzetti A, Riva A, Kamysz E, Scalise G.

Peptides. 2007 Aug;28(8):1509-13. Epub 2007 Jul 17.

PMID:
17698253
37.

Comparative efficacy of topical versus systemic teicoplanin in experimental model of wound infections.

Ghiselli R, Cirioni O, Giacometti A, Scalise A, Simonetti O, Mocchegiani F, Orlando F, Goteri G, Della Vittoria A, Filosa A, Silvestri C, Offidani A, Bertani A, Scalise G, Saba V.

J Surg Res. 2008 Jan;144(1):74-81. Epub 2007 Jun 14.

PMID:
17574587
38.

The lipopeptides Pal-Lys-Lys-NH(2) and Pal-Lys-Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection.

Cirioni O, Giacometti A, Ghiselli R, Kamysz W, Silvestri C, Orlando F, Mocchegiani F, Vittoria AD, Kamysz E, Saba V, Scalise G.

Peptides. 2007 Jun;28(6):1299-303. Epub 2007 Mar 31.

PMID:
17537542
39.

The bioartificial thyroid: a biotechnological perspective in endocrine organ engineering for transplantation replacement.

Toni R, Casa CD, Spaletta G, Marchetti G, Mazzoni P, Bodria M, Ravera S, Dallatana D, Castorina S, Riccioli V, Castorina EG, Antoci S, Campanile E, Raise G, Rossi R, Ugolotti G, Martorella A, Roti E, Sgallari F, Pinchera A.

Acta Biomed. 2007;78 Suppl 1:129-55. Erratum in: Acta Biomed. 2007;78(2):152. Scalise, Gabriella [corrected to Raise, Gabriella]; Rossio, Raffaella [corrected to Rossi, Raffaella]; Ugolottio, Giorgio [corrected to Ugolotti, Giorgio]; Rot, Elio [corrected to Roti, Elio].

PMID:
17465331
40.

Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain.

Cirioni O, Ghiselli R, Orlando F, Silvestri C, Mocchegiani F, Rocchi M, Chiodi L, Abbruzzetti A, Saba V, Scalise G, Giacometti A.

Crit Care Med. 2007 Jul;35(7):1717-23.

PMID:
17452938
41.

In vitro activity of synthetic antimicrobial peptides against Candida.

Kamysz W, Nadolski P, Kedzia A, Cirioni O, Barchiesi F, Giacometti A, Scalise G, Lukasiak J, Okrój M.

Pol J Microbiol. 2006;55(4):303-7.

PMID:
17416067
42.

Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain.

Cirioni O, Ghiselli R, Silvestri C, Kamysz W, Orlando F, Mocchegiani F, Di Matteo F, Riva A, Lukasiak J, Scalise G, Saba V, Giacometti A.

Antimicrob Agents Chemother. 2007 Jun;51(6):2005-10. Epub 2007 Apr 2.

43.

Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.

Balaban N, Cirioni O, Giacometti A, Ghiselli R, Braunstein JB, Silvestri C, Mocchegiani F, Saba V, Scalise G.

Antimicrob Agents Chemother. 2007 Jun;51(6):2226-9. Epub 2007 Mar 19.

44.

In vitro activities of tachyplesin III against Pseudomonas aeruginosa.

Cirioni O, Giacometti A, Kamysz W, Silvestri C, Riva A, Della Vittoria A, Abbruzzetti A, Lukasiak J, Scalise G.

Peptides. 2007 Apr;28(4):747-51. Epub 2007 Jan 13.

PMID:
17331619
45.

Fluconazole susceptibility of Candida spp. isolates collected over nine years in a teaching hospital of Ancona, Italy.

Barchiesi F, Arzeni D, Greganti G, Marigliano A, Tomassetti S, Spreghini E, Scalise G.

J Chemother. 2007 Feb;19(1):58-61.

PMID:
17309852
46.

In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.

Giacometti A, Cirioni O, Riva A, Kamysz W, Silvestri C, Nadolski P, Della Vittoria A, Łukasiak J, Scalise G.

Antimicrob Agents Chemother. 2007 Apr;51(4):1494-6. Epub 2007 Jan 12.

47.

Caspofungin in combination with amphotericin B against Candida parapsilosis.

Barchiesi F, Spreghini E, Tomassetti S, Giannini D, Scalise G.

Antimicrob Agents Chemother. 2007 Mar;51(3):941-5. Epub 2006 Dec 11.

48.

Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection.

Giacometti A, Cirioni O, Ghiselli R, Orlando F, Silvestri C, Renzone G, Testa I, Mocchegiani F, Della Vittoria A, Saba V, Scaloni A, Scalise G.

J Biomed Mater Res A. 2007 Apr;81(1):233-9.

PMID:
17120214
49.

RNAIII-inhibiting-peptide-loaded polymethylmethacrylate prevents in vivo Staphylococcus aureus biofilm formation.

Anguita-Alonso P, Giacometti A, Cirioni O, Ghiselli R, Orlando F, Saba V, Scalise G, Sevo M, Tuzova M, Patel R, Balaban N.

Antimicrob Agents Chemother. 2007 Jul;51(7):2594-6. Epub 2006 Nov 20.

50.

In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci.

Kamysz W, Silvestri C, Cirioni O, Giacometti A, Licci A, Della Vittoria A, Okroj M, Scalise G.

Antimicrob Agents Chemother. 2007 Jan;51(1):354-8. Epub 2006 Oct 23.

Supplemental Content

Loading ...
Support Center